Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 23, 2021BMC CancerOpen Access

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDavid J. PinatoUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro”ACAlessio CortelliniCampus Bio Medico University HospitalASAjithkumar SukumaranManchester University NHS Foundation Trust

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pinato et al. (2021) studied this question.

synapsesocial.com/papers/6a86704c2f38e7aabb2ee326https://doi.org/10.1186/s12885-021-08033-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic effect of transarterial chemoembolization–induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma2017 · 34 citations
  2. 2Global cancer statistics2011 · 55,020 citations
  3. 3Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 1432017 · 497 citations
  4. 4The place of downstaging for hepatocellular carcinoma2010 · 143 citations
  5. 5CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer2018 · 639 citations